Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force Dermatology for Cancer Patients International Study

    July 2023 in “ Cancers
    Pietro Sollena, Vasiliki Nikolaou, Ηλίας Κοττέας, Alexander J. Stratigos, Davide Fattore, Armando Orlandi, Maria Mannino, Marcello Di Pumpo, Monika Fida, Michela Starace, Zoé Apalla, Maria Romano, Julia Riganti, Sònia Segura, Azael Freites-Martínez, Gabriella Fabbrocini, V. Sibaud, Ketty Peris
    Image
    Studysummary In this multicentric retrospective study, researchers reported that cutaneous adverse events were common among advanced breast cancer patients treated with cyclin-dependent kinase inhibitors (CDK4/6i), generally mild, and manageable with topical treatments, though in some cases, they led to treatment discontinuation.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →

    Research cited in this study

    4 / 4 results